New One-Dose Drug Approved to Fight Sleeping Sickness in Africa

A new, single-dose drug for human African trypanosomiasis – commonly known as sleeping sickness – has been approved by European regulators, offering a potentially transformative step towards eradicating the neglected tropical disease. The approval, announced this week, simplifies treatment considerably and raises hopes for a future free from this ancient burden, particularly across sub-Saharan Africa where the disease remains a significant public health challenge.

What is Sleeping Sickness?

Human African trypanosomiasis is a parasitic disease transmitted by the bite of infected tsetse flies. It occurs in 36 countries in sub-Saharan Africa. Left untreated, the disease is almost invariably fatal. The early stages involve fever, headaches, joint pains, and itching. As the disease progresses, it affects the central nervous system, leading to neurological symptoms like confusion, sensory disturbances, and sleep cycle disruption – hence the name “sleeping sickness.” There are two forms of the disease, caused by different parasites: Trypanosoma brucei gambiense, which accounts for over 95% of cases and causes a chronic infection, and Trypanosoma brucei rhodesiense, which causes an acute infection.

A Simpler Treatment Pathway

Historically, treating sleeping sickness has been complex and challenging. Existing treatments often require multiple injections, lengthy hospital stays, and can have significant side effects. The new drug, fexinidazole, developed by the non-profit DNDi (Drugs for Neglected Diseases initiative), offers a dramatically simplified approach. It’s administered as a single oral dose, meaning patients no longer need to be hospitalized for extended periods or endure painful injections. This is particularly crucial in remote areas with limited healthcare infrastructure. The drug has been shown to be effective against T. B. Gambiense, the form of the disease responsible for the vast majority of cases. Science.org reports that clinical trials have demonstrated high cure rates with minimal adverse effects.

Impact on African Countries

The approval by the European Medicines Agency (EMA) is a critical step, but ensuring access to the drug in affected African countries is the next hurdle. The DNDi is working with national control programs to facilitate rollout. However, the broader context of EU regulations and sustainability requirements impacting African nations is complex. Recent EU directives aimed at ensuring sustainability in value chains, such as the Carbon Border Adjustment Mechanism (CBAM), could inadvertently create trade barriers and financial burdens for African countries. CONCITO highlights that while these regulations are intended to promote a green transition, they require significant investment and capacity building within African nations to meet the new standards. Without targeted support, these regulations could hinder economic development and access to essential medicines like fexinidazole.

The CBAM and Potential Costs

The CBAM, for example, is set to impose a carbon tax on imports of certain goods, including steel, aluminum, cement, and fertilizers. EcoFin Agency reports that Africa could lose $27 billion in exports annually due to CBAM rules, impacting key sectors in countries like Mozambique, South Africa, Morocco, and Egypt. While African countries have begun exploring domestic carbon taxes, the costs associated with monitoring, reporting, and verification (MRV) could be substantial – potentially consuming 0.5–1.5% of their GDP. The EU would retain the revenue from CBAM if these MRV systems aren’t recognized, further exacerbating the financial strain.

Evidence and Limitations

The efficacy of fexinidazole has been demonstrated in several clinical trials. However, it’s key to note that the drug is currently only approved for the treatment of the chronic form of sleeping sickness caused by T. B. Gambiense. It is not yet effective against the acute form caused by T. B. Rhodesiense, which, while less common, is more aggressive and requires different treatment strategies. Further research is needed to develop effective treatments for this form of the disease. The long-term effects of fexinidazole are still being monitored, and ongoing surveillance is crucial to identify any potential adverse events.

Public Health Implications and Next Steps

The availability of a simple, oral treatment for the chronic form of sleeping sickness represents a major advancement in global health. It will significantly reduce the burden on healthcare systems in affected countries and improve the quality of life for patients. However, eradication requires a multifaceted approach. Continued investment in vector control – reducing the population of tsetse flies – is essential. Improved surveillance systems are needed to detect and respond to outbreaks quickly. And, crucially, international collaboration and financial support are vital to ensure that all affected countries have access to the new drug and the resources needed to implement comprehensive control programs.

The European Medicines Agency approval triggers a series of procedural steps. National regulatory authorities in African countries will now review the data and decide whether to approve fexinidazole for use within their borders. The World Health Organization (WHO) will likely update its treatment guidelines to reflect the availability of this new drug. Ongoing pharmacovigilance – monitoring the safety and effectiveness of the drug in real-world settings – will be critical to inform future recommendations and ensure optimal patient care. The DNDi and partner organizations will continue to monitor the rollout of fexinidazole and provide technical support to national control programs.